<DOC>
	<DOC>NCT02090673</DOC>
	<brief_summary>The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Exenatide through collecting, reviewing, identifying and verifying the safety and effectiveness information about Exenatide in general practice.</brief_summary>
	<brief_title>Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Male or female at least 18 years of age Patients who are to initiate Exenatide treatment for type 2 diabetes at baseline, following their treating physicians' advice Patients, who in the opinion of the treating physicians, comply with all the recommendations stated in the relevant product information Are simultaneously participating in a different study that includes a treatment intervention and/or an investigational drug Are pregnant or have intentions of becoming pregnant within the duration of the study Contraindications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>